https://corcept.com/wp-content/uploads/COR-logo.svg00jeremiah@devisedesigns.comhttps://corcept.com/wp-content/uploads/COR-logo.svgjeremiah@devisedesigns.com2023-01-13 00:00:002023-01-13 00:00:00Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
https://corcept.com/wp-content/uploads/COR-logo.svg00jeremiah@devisedesigns.comhttps://corcept.com/wp-content/uploads/COR-logo.svgjeremiah@devisedesigns.com2021-08-18 00:00:002021-08-18 00:00:00Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study
https://corcept.com/wp-content/uploads/COR-logo.svg00jeremiah@devisedesigns.comhttps://corcept.com/wp-content/uploads/COR-logo.svgjeremiah@devisedesigns.com2020-09-04 00:00:002020-09-04 00:00:00A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study to Assess the Ef cacy and Safety of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Patients With Hypercortisolism Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
